141 related articles for article (PubMed ID: 17879419)
1. Sudden hearing loss associated with peginterferon and ribavirin combination therapy during hepatitis C treatment.
Elloumi H; Houissa F; Hadj NB; Gargouri D; Romani M; Kharrat J; Ghorbel A
World J Gastroenterol; 2007 Oct; 13(40):5411-2. PubMed ID: 17879419
[TBL] [Abstract][Full Text] [Related]
2. [A case of sudden-onset hearing loss in a patient treated with peginterferon alpha-2b and ribavirin for chronic hepatitis C].
Shin MK; Kim TH; Ju K; Ha CY; Min HJ; Jung WT; Lee OJ
Korean J Hepatol; 2009 Sep; 15(3):370-4. PubMed ID: 19783887
[TBL] [Abstract][Full Text] [Related]
3. Pegylated interferon/ribavirin-associated sudden hearing loss in a patient with chronic hepatitis C in Brazil.
Mendes-Corrêa MC; Bittar RS; Salmito N; Oiticica J
Braz J Infect Dis; 2011; 15(1):87-9. PubMed ID: 21412597
[TBL] [Abstract][Full Text] [Related]
4. Acute sensorineural hearing loss associated with peginterferon and ribavirin combination therapy during hepatitis C treatment: outcome after resumption of therapy.
Wong VK; Cheong-Lee C; Ford JA; Yoshida EM
World J Gastroenterol; 2005 Sep; 11(34):5392-3. PubMed ID: 16149154
[TBL] [Abstract][Full Text] [Related]
5. Sudden hearing loss in patients with chronic hepatitis C treated with pegylated interferon/ribavirin.
Formann E; Stauber R; Denk DM; Jessner W; Zollner G; Munda-Steindl P; Gangl A; Ferenci P
Am J Gastroenterol; 2004 May; 99(5):873-7. PubMed ID: 15128353
[TBL] [Abstract][Full Text] [Related]
6. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses.
Liu CJ; Chuang WL; Lee CM; Yu ML; Lu SN; Wu SS; Liao LY; Chen CL; Kuo HT; Chao YC; Tung SY; Yang SS; Kao JH; Liu CH; Su WW; Lin CL; Jeng YM; Chen PJ; Chen DS
Gastroenterology; 2009 Feb; 136(2):496-504.e3. PubMed ID: 19084016
[TBL] [Abstract][Full Text] [Related]
7. R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin.
Pockros PJ; Nelson D; Godofsky E; Rodriguez-Torres M; Everson GT; Fried MW; Ghalib R; Harrison S; Nyberg L; Shiffman ML; Najera I; Chan A; Hill G
Hepatology; 2008 Aug; 48(2):385-97. PubMed ID: 18570306
[TBL] [Abstract][Full Text] [Related]
8. Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin.
Fried MW; Jensen DM; Rodriguez-Torres M; Nyberg LM; Di Bisceglie AM; Morgan TR; Pockros PJ; Lin A; Cupelli L; Duff F; Wang K; Nelson DR
Hepatology; 2008 Oct; 48(4):1033-43. PubMed ID: 18697207
[TBL] [Abstract][Full Text] [Related]
9. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.
Hézode C; Forestier N; Dusheiko G; Ferenci P; Pol S; Goeser T; Bronowicki JP; Bourlière M; Gharakhanian S; Bengtsson L; McNair L; George S; Kieffer T; Kwong A; Kauffman RS; Alam J; Pawlotsky JM; Zeuzem S;
N Engl J Med; 2009 Apr; 360(18):1839-50. PubMed ID: 19403903
[TBL] [Abstract][Full Text] [Related]
10. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.
Angelico M; Koehler-Horst B; Piccolo P; Angelico F; Gentile S; Francioso S; Tarquini P; Vecchia RD; Ponti L; Pilleri G; Barlattani A; Grieco A; Soccorsi F; Guarascio P; Demelia L; Sorbello O; Rossi Z; Forlini G; Zaru S; Bandiera F;
Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):680-7. PubMed ID: 18679072
[TBL] [Abstract][Full Text] [Related]
11. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J
N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553
[TBL] [Abstract][Full Text] [Related]
12. Reversible sudden hearing loss in a chronic hepatitis C patient who achieved a sustained response to antiviral re-treatment.
Zampino R; Costa G; Barillari M; Adinolfi LE; Marrone A
Infez Med; 2012 Jun; 20(2):117-9. PubMed ID: 22767311
[TBL] [Abstract][Full Text] [Related]
13. Peginterferon alpha-2a and ribavirin in patients with hepatitis C virus genotype 1 infection with persistently normal alanine aminotransferase levels.
Calleja JL; García-Samaniego J; Ruiz-Antorán B; Trapero M; Morillas R; de la Revilla J; Erdozaín JC; Espinosa MD; Suárez D; Solá R; Romero-Gómez M; Baños F; Alvarez MA;
J Gastroenterol Hepatol; 2012 Nov; 27(11):1705-10. PubMed ID: 22742958
[TBL] [Abstract][Full Text] [Related]
14. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.
Chung RT; Andersen J; Volberding P; Robbins GK; Liu T; Sherman KE; Peters MG; Koziel MJ; Bhan AK; Alston B; Colquhoun D; Nevin T; Harb G; van der Horst C;
N Engl J Med; 2004 Jul; 351(5):451-9. PubMed ID: 15282352
[TBL] [Abstract][Full Text] [Related]
15. Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin.
Buti M; Sanchez-Avila F; Lurie Y; Stalgis C; Valdés A; Martell M; Esteban R
Hepatology; 2002 Apr; 35(4):930-6. PubMed ID: 11915041
[TBL] [Abstract][Full Text] [Related]
16. Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy.
Sherman M; Yoshida EM; Deschenes M; Krajden M; Bain VG; Peltekian K; Anderson F; Kaita K; Simonyi S; Balshaw R; Lee SS;
Gut; 2006 Nov; 55(11):1631-8. PubMed ID: 16709661
[TBL] [Abstract][Full Text] [Related]
17. Re-treatment of previous non-responders and relapsers to interferon plus ribavirin with peginterferon alfa-2a (40KD), ribavirin ± amantadine in patients with chronic hepatitis C: randomized multicentre clinical trial.
Pessôa MG; Cheinquer H; Almeida PR; Silva GF; Lima MP; Paraná R; Lacerda MA; Parise ER; Pernambuco JR; Pedrosa SS; Teixeira R; Sette H; Tatsch F
Ann Hepatol; 2012; 11(1):52-61. PubMed ID: 22166561
[TBL] [Abstract][Full Text] [Related]
18. Spotlight on peginterferon-alpha-2a (40 kD) plus ribavirin in the management of chronic hepatitis C mono-infection.
Keam SJ; Cvetković RS
BioDrugs; 2009; 23(1):63-8. PubMed ID: 19344193
[TBL] [Abstract][Full Text] [Related]
19. Recurrent myocardial ischaemia during combination antiviral therapy in a patient with chronic hepatitis C and normal aminotransferase levels.
Lenci I; Piccolo P; Francioso S; Di Paolo D; Galante A; Angelico M
Dig Liver Dis; 2008 Sep; 40(9):785-90. PubMed ID: 17913610
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of peginterferon α-2a (40 kD) plus ribavirin among patients with chronic hepatitis C and earlier treatment failure to interferon and ribavirin: an open-label study in central and Eastern Europe.
Husa P; Oltman M; Ivanovski L; Rehák V; Messinger D; Tietz A; Urbanek P
Eur J Gastroenterol Hepatol; 2011 May; 23(5):375-81. PubMed ID: 21502923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
